This final article in the series has two purposes: to summarize all the considerations that go into a company’s compendial affairs program and to look ahead at topics that will likely result in ...

As pharmaceutical companies increasingly rely on artificial intelligence (AI) to optimise trial processes, the potential for AI models to drift over time poses significant risks to trial integrity ...